Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug (GlobeNewswire) - Apr 28, 2025 - "Silo Pharma, Inc...today announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer’s disease (AD) exclusively licensed to Silo Pharma from Columbia University....The patent, titled 'Compositions and Methods for the Treatment of Alzheimer’s Disease and Other Neurogenerative Disease,' covers SPC-14’s novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD."
Patent • Alzheimer's Disease
|